258 related articles for article (PubMed ID: 8170967)
1. A faster-acting and more potent form of tissue plasminogen activator.
Keyt BA; Paoni NF; Refino CJ; Berleau L; Nguyen H; Chow A; Lai J; Peña L; Pater C; Ogez J
Proc Natl Acad Sci U S A; 1994 Apr; 91(9):3670-4. PubMed ID: 8170967
[TBL] [Abstract][Full Text] [Related]
2. New variant of human tissue plasminogen activator (TPA) with enhanced efficacy and lower incidence of bleeding compared with recombinant human TPA.
Benedict CR; Refino CJ; Keyt BA; Pakala R; Paoni NF; Thomas GR; Bennett WF
Circulation; 1995 Nov; 92(10):3032-40. PubMed ID: 7586274
[TBL] [Abstract][Full Text] [Related]
3. Real-time measurement of lysis of mural platelet deposits by fibrinolytic agents under arterial flow.
Graham DA; Huang TC; Keyt BA; Alevriadou BR
Ann Biomed Eng; 1998; 26(4):712-24. PubMed ID: 9662163
[TBL] [Abstract][Full Text] [Related]
4. A variant of t-PA (T103N, KHRR 296-299 AAAA) that, by bolus, has increased potency and decreased systemic activation of plasminogen.
Refino CJ; Paoni NF; Keyt BA; Pater CS; Badillo JM; Wurm FM; Ogez J; Bennett WF
Thromb Haemost; 1993 Aug; 70(2):313-9. PubMed ID: 8236141
[TBL] [Abstract][Full Text] [Related]
5. Clot penetration and retention by plasminogen activators promote fibrinolysis.
Marcos-Contreras OA; Ganguly K; Yamamoto A; Shlansky-Goldberg R; Cines DB; Muzykantov VR; Murciano JC
Biochem Pharmacol; 2013 Jan; 85(2):216-22. PubMed ID: 23098998
[TBL] [Abstract][Full Text] [Related]
6. Pharmacokinetics of a slower clearing tissue plasminogen activator variant, TNK-tPA, in patients with acute myocardial infarction.
Modi NB; Eppler S; Breed J; Cannon CP; Braunwald E; Love TW
Thromb Haemost; 1998 Jan; 79(1):134-9. PubMed ID: 9459338
[TBL] [Abstract][Full Text] [Related]
7. A slow clearing, fibrin-specific, PAI-1 resistant variant of t-PA (T103N, KHRR 296-299 AAAA).
Paoni NF; Keyt BA; Refino CJ; Chow AM; Nguyen HV; Berleau LT; Badillo J; Peña LC; Brady K; Wurm FM
Thromb Haemost; 1993 Aug; 70(2):307-12. PubMed ID: 8236140
[TBL] [Abstract][Full Text] [Related]
8. Identification of the mechanism responsible for the increased fibrin specificity of TNK-tissue plasminogen activator relative to tissue plasminogen activator.
Stewart RJ; Fredenburgh JC; Leslie BA; Keyt BA; Rischke JA; Weitz JI
J Biol Chem; 2000 Apr; 275(14):10112-20. PubMed ID: 10744692
[TBL] [Abstract][Full Text] [Related]
9. TNK-tissue plasminogen activator in acute myocardial infarction. Results of the Thrombolysis in Myocardial Infarction (TIMI) 10A dose-ranging trial.
Cannon CP; McCabe CH; Gibson CM; Ghali M; Sequeira RF; McKendall GR; Breed J; Modi NB; Fox NL; Tracy RP; Love TW; Braunwald E
Circulation; 1997 Jan; 95(2):351-6. PubMed ID: 9008448
[TBL] [Abstract][Full Text] [Related]
10. A long-half-life and fibrin-specific form of tissue plasminogen activator in rabbit models of embolic stroke and peripheral bleeding.
Thomas GR; Thibodeaux H; Errett CJ; Badillo JM; Keyt BA; Refino CJ; Zivin JA; Bennett WF
Stroke; 1994 Oct; 25(10):2072-8; discussion 2078-9. PubMed ID: 8091454
[TBL] [Abstract][Full Text] [Related]
11. Recombinant human C1-inhibitor prevents non-specific proteolysis by mutant pro-urokinase during optimal fibrinolysis.
Gurewich V; Pannell R
Thromb Haemost; 2009 Aug; 102(2):279-86. PubMed ID: 19652878
[TBL] [Abstract][Full Text] [Related]
12. Synergistic fibrinolysis: The combined effects of tissue plasminogen activator and recombinant staphylokinase in vitro.
Aisina R; Mukhametova L; Varfolomeyev S
Biochim Biophys Acta; 2016 Apr; 1860(4):629-35. PubMed ID: 26723174
[TBL] [Abstract][Full Text] [Related]
13. Fibrin-specificity of a plasminogen activator affects the efficiency of fibrinolysis and responsiveness to ultrasound: comparison of nine plasminogen activators in vitro.
Sakharov DV; Barrertt-Bergshoeff M; Hekkenberg RT; Rijken DC
Thromb Haemost; 1999 Apr; 81(4):605-12. PubMed ID: 10235448
[TBL] [Abstract][Full Text] [Related]
14. Tissue-type plasminogen activator-binding RNA aptamers inhibiting low-density lipoprotein receptor family-mediated internalisation.
Bjerregaard N; Bøtkjær KA; Helsen N; Andreasen PA; Dupont DM
Thromb Haemost; 2015 Jul; 114(1):139-49. PubMed ID: 25855589
[TBL] [Abstract][Full Text] [Related]
15. Kringle glycosylation in a modified human tissue plasminogen activator improves functional properties.
Berg DT; Burck PJ; Berg DH; Grinnell BW
Blood; 1993 Mar; 81(5):1312-22. PubMed ID: 8382971
[TBL] [Abstract][Full Text] [Related]
16. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia.
Sauls DL; Lockhart E; Warren ME; Lenkowski A; Wilhelm SE; Hoffman M
Biochemistry; 2006 Feb; 45(8):2480-7. PubMed ID: 16489740
[TBL] [Abstract][Full Text] [Related]
17. Recombinant variants of tissue-type plasminogen activator containing amino acid substitutions in the finger domain.
Yahara H; Matsumoto K; Maruyama H; Nagaoka T; Ikenaka Y; Yajima K; Fukao H; Ueshima S; Matsuo O
Thromb Haemost; 1992 Dec; 68(6):672-7. PubMed ID: 1287881
[TBL] [Abstract][Full Text] [Related]
18. Characterization of the murine plasma fibrinolytic system.
Lijnen HR; van Hoef B; Beelen V; Collen D
Eur J Biochem; 1994 Sep; 224(3):863-71. PubMed ID: 7523120
[TBL] [Abstract][Full Text] [Related]
19. Involvement of residues 296-299 in the enzymatic activity of tissue-type plasminogen activator.
Paoni NF; Refino CJ; Brady K; Peña LC; Nguyen HV; Kerr EM; Johnson AC; Wurm FM; van Reis R; Botstein D
Protein Eng; 1992 Apr; 5(3):259-66. PubMed ID: 1409547
[TBL] [Abstract][Full Text] [Related]
20. Incidence and predictors of bleeding events after fibrinolytic therapy with fibrin-specific agents: a comparison of TNK-tPA and rt-PA.
Van de Werf F; Barron HV; Armstrong PW; Granger CB; Berioli S; Barbash G; Pehrsson K; Verheugt FW; Meyer J; Betriu A; Califf RM; Li X; Fox NL;
Eur Heart J; 2001 Dec; 22(24):2253-61. PubMed ID: 11728145
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
